Open AccessLiver Fibrosis Progression and Mortality in Hepatitis B– and C–Coinfected Persons Treated With Directly Acting Antiviral Agents: Results From ERCHIVES
Author(s) -
Adeel A. Butt,
Peng Yan,
Samia Aslam,
AbdulBadi AbouSamra,
Kenneth E. Sherman,
Obaid S. Shaikh
Publication year - 2019
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciz1097
Subject(s) - medicine , cirrhosis , hepatitis c virus , confidence interval , gastroenterology , incidence (geometry) , hepatitis b virus , hepatitis c , fibrosis , hepatitis b , chronic hepatitis , immunology , virus , physics , optics
For persons with baseline Fibrosis-4 1.46-3.25, cirrhosis incidence/1000 patient-years was 49.3 among hepatitis B virus (HBV)/hepatitis C virus (HCV) coinfected and 18.2 among HCV monoinfected (P = .03). Cirrhosis risk was numerically higher but statistically nonsignificant among HBV/HCV coinfected (hazards ratio [HR] 1.51; 95% confidence intervals [CI], .37-6.05) but lower among those who attained sustained virologic response (HR, .52; 95% CI, .42-.63).